Introduction {#Sec1}
============

Extracellular nucleotides modulate a multiplicity of tissue functions including development, blood flow, secretion, inflammation and immune reactions. Indeed, signaling via extracellular nucleotides has been recognized for over a decade as one of the most ubiquitous intercellular signaling mechanisms \[[@CR1], [@CR2]\]. Essentially every cell in a mammalian organism leaks or releases these mediators, and carries receptors for nucleotides of which seven ionotropic (P2X) and at least eight metabotropic (P2Y) receptor subtypes have been identified and characterized to date. Whereas P2X receptors respond to ATP, P2Y receptors can be activated by ATP, ADP, UTP, UDP, ITP, and nucleotide sugars, albeit agonist specificity varies between subtypes and the multiple animal species \[[@CR3]\]. Depending on the P2 receptor subtype and signaling pathways involved, these receptors trigger and mediate short-term (acute) processes that affect cellular metabolism, adhesion, activation or migration. In addition, purinergic signaling also has profound impacts upon other more protracted responses, including cell proliferation, differentiation and apoptosis, such as seen in atherosclerosis, degenerative neurological diseases and in several inflammatory conditions \[[@CR2], [@CR4], [@CR5]\].

The effects of extracellular nucleotides appear to overlap, at least in part, with those of vascular growth factors, cytokines (inflammatory), adhesion molecules and nitric oxide (NO). Nucleotide-mediated activation may be also synergistic with polypeptide growth factors (PDGF, bFGF) and insulin, the signaling being mediated via phospholipase C and D, diacylglycerol, protein kinase C, ERKs, phosphatidylinositol 3-kinases (PI3K), MAP kinases (MAPK) and Rho \[[@CR6]--[@CR8]\]. The situation concerning extracellular nucleotide-signaling can be suitably contrasted with the unique specificity of peptide hormones or vasoactive factors for often single, defined receptors \[[@CR9], [@CR10]\]. Within purinergic/pyrimidinergic signaling events specificity is dictated by three essential modulatory components: 1) The derivation or source of the extracellular nucleotides \[[@CR1], [@CR11], [@CR12]\]; 2) the expression of specific receptors for these molecular transmitters (and for the nucleotide and nucleoside derivatives) \[[@CR13]--[@CR16]\] (See also Molecular Recognition Section of National Institutes of Health, <http://mgddk1.niddk.nih.gov/> also <http://www.ensembl.org/index.html> and <http://www.geocities.com/bioinformaticsweb/speciesspecificdatabases.htm>), and, 3) select ectonucleotidases that dictate the cellular responses by the stepwise degradation of extracellular nucleotides to nucleosides \[[@CR17]--[@CR20]\].

Ensembles of ectonucleotidases, associated receptors and signaling molecules {#Sec2}
============================================================================

Within the past decade, ectonucleotidases belonging to several enzyme families have been discovered, cloned and functionally characterized by pharmacological means. Specifically, we refer here to members of the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family (EC 3.6.1.5) as ectoenzymes that hydrolyze extracellular nucleoside tri-and diphosphates and have a defined pharmacological profile. Most notably, in many tissues and cells, NTPDases comprise dominant parts of a complex cell surfacelocated nucleotide hydrolyzing and interconverting machinery. This ensemble includes the ecto-nucleotide pyrophosphatase phosphodiesterases (E-NPPs), NADglycohydrolases, CD38/NADase, alkaline phosphatases, dinucleoside polyphosphate hydrolases, adenylate kinase, nucleoside diphosphate kinase, and potentially ecto-F1-Fo ATP synthases \[[@CR21]--[@CR25]\] that may interact in various tissues and cellular systems.

The ectonucleotidase chain or cascade, as initiated by NTPDases can be terminated by ecto-5′-nucleotidase (CD73; EC 3.1.3.5) with hydrolysis of nucleoside monophosphates \[[@CR26]\]. Together, ecto-5′-nucleotidase and adenosine deaminase (ADA; EC 3.5.4.4), another ectoenzyme that is involved in purine salvage pathways and converts adenosine to inosine, closely regulate local and pericellular extracellular and plasma concentrations of adenosine \[[@CR10], [@CR27]\].

Several of these ectonucleotidase families and additional functions of NTPDases \[[@CR28]--[@CR30]\] are addressed elsewhere in this issue in detail. This review focuses on the surface-located mammalian members of the E-NTPDase protein family. It starts with a brief introduction of molecular structure and functional properties, followed by an analysis of the physiological and pathophysiological roles at various sites with an emphasis on vasculature and neural tissues.

Molecular identities unraveled {#Sec3}
==============================

The literature on the molecular and functional characterization of the E-NTPDase family has been intensively reviewed \[[@CR18]--[@CR22], [@CR31]--[@CR36]\] and will not be repeated here in detail. Our intent is to summarize principal properties of the enzymes that will be of use for the reader new to this field.

Eight different *ENTPD* genes (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}) encode members of the NTPDase protein family. Four of the NTPDases are typical cell surface-located enzymes with an extracellularly facing catalytic site (NTPDase1, 2, 3, 8). NTPDases 5 and 6 exhibit intracellular localization and undergo secretion after heterologous expression. NTPDases 4 and 7 are entirely intracellularly located, facing the lumen of cytoplasmic organelles (Fig. [1](#Fig1){ref-type="fig"}). The molecular identification of individual NTPDase subtypes, genetic engineering, mutational analyses, and the generation of subtypespecific antibodies have not only led to considerable insight into enzyme structure and function. These advances have also defined physiological and pathophysiological functions of NTPDases in a considerable variety of tissues. Table 1Nomenclature of mammalian members of the E-NTPDase family and chromosomal localizationProtein nameAdditional namesGene name human, mouseChromosome location human, mouseAccession number human, mouseNTPDaselCD39, ATPDase, ecto-apyrase \[[@CR43], [@CR44]\]*ENTPD1, Entpdl*10q24, 19C3U87967, NMJ309848NTPDase2CD39L1, ecto-ATPase \[[@CR49], [@CR109], [@CR252]\]*ENTPD2, Entpdl*9q34, 2A3AF144748, AY376711NTPDase3CD39L3, HB6 \[[@CR50], [@CR177]\]*ENTPD3, Entpd3*3p21.3, 9F4AF034840, AY376710NTPDase4UDPase, LALP70 \[[@CR253], [@CR254]\]*ENTPD4, Entpd4*8p21, 14D1AF016032, NMJ326174NTPDase5CD39L4, ER-UDPase, PCPH \[[@CR137], [@CR255], [@CR256]\]*ENTPD5, Entpd5*14q24, 12E (12D1)^a^AF039918, AJ238636NTPDase6CD39L2 \[[@CR257]--[@CR259]\]*ENTPD6, Entpd6*20p11.2, 2G3AY327581, NM_172117NTPDase7LALP1 \[[@CR260]\]*ENTPD7, Entpd7*10q24, 19D1 (19C3)^a^AF269255, AF288221NTPDase8liver canalicular ecto-ATPase, hATPDase \[[@CR52], [@CR174]\]*ENTPD8, Entpd8*9q34, 2A3AY430414, AY364442Information is provided for the human genome from GenBank (<http://www.ncbi.nlm.nih.gov>) and mouse genome informatics (MGI) for the mouse genome (<http://www.informatics.jax.org/>). Since the mouse genome represents a composite assembly that continues to undergo updates and changes from build to build, the computed map locations may be corrected in the future.^a^ For mouse *Entpd5* and *Entpd7*, the BLAST analysis displayed in Map Viewer indicates a different map location (in brackets) when compared with the mapping data reported on MGI records using cytoband information based on experimental evidence.Fig. 1Hypothetical phylogenetic tree derived for 22 selected members of the E-NTPDase family (NTPDase1 to NTPDase8) from rat (*r*), human (*h*) and mouse (*m*), following alignment of amino acid sequences. The *length of the lines* indicates the differences between amino acid sequences. The *graph* depicts a clear separation between surface-located (*top*) and intracellular (*bottom*) NTPDases. In addition, the major substrate preferences of individual subtypes and the predicted membrane topography for each group of enzymes is given (one or two transmembrane domains, indicated by *barrels*). Modified from \[[@CR59]\].

The presence of ATP and/or ADP hydrolyzing activity at the surface of many cell types had been recognized for several decades \[[@CR17], [@CR37]--[@CR40]\]. However, the molecular identity of the first member of the ENTPDase family (NTPDase1) was not unraveled and determined until the mid-1990s. The prototypic member of the enzyme family had first been cloned and sequenced as a lymphocyte cell activation (CD39) antigen of undetermined function \[[@CR41]\]. Final success came from three independent approaches. Handa and Guidotti \[[@CR42]\] purified and cloned a soluble ATP diphosphohydrolase (apyrase) from potato tubers and noted that this protein was related not only to similar enzymes of some protozoans, plants and yeast but also to human CD39. They also recognized conserved sequence domains and the relation to members of the actin-hsp70-hexokinase superfamily. This was then followed by the functional expression of human CD39 and the demonstration that this protein was in fact an ecto-apyrase \[[@CR43]\]. In parallel, ectonucleotidases (termed ATP diphosphohydrolases) from porcine pancreas and bovine aorta were purified. The partial amino acid sequences for both ATP diphosphohydrolases revealed identity with the cloned cDNA sequence of CD39 \[[@CR44]\]. The cDNA was isolated from human endothelial cells and functional, thromboregulatory studies confirmed that the dominant vascular ectonucleotidase (ATP diphosphohydrolase) activity was identical to the previously described and cloned human CD39 \[[@CR44]\]. Several internal peptide sequences obtained from the purified human placental ATP diphosphohydrolase \[[@CR45]\] revealed that in retrospect this protein was also identical to CD39.

It was originally thought that there existed a single ectonucleotidase of the NTPDase type with potential post-translational modifications \[[@CR46]\]. However, a close molecular relative was soon cloned that revealed functional properties of an ecto-ATPase (now NTPDase2) rather than of an ecto-ATP diphosphohydrolase \[[@CR47], [@CR48]\]. Further human genomic analysis of expressed sequence tags (ESTs) allowed the identifi-cation of additional members of the gene family \[[@CR49]--[@CR51]\]. These genes were originally named *CD39L(ike)1* to *CD39L4*. Then followed the identification, cloning and functional expression of all members of the ENTPDase family, the last to date being NTPDase8 \[[@CR52]\].

Potential splice variants have been isolated for the surface-located NTPDase1 and NTPDase2 \[for references see [@CR34], [@CR53]\]. It should be further noted that heterologous expression of potential splice variants does not necessarily result in the formation of a functional protein \[[@CR54]\].

The initially proposed nomenclature \[[@CR50]\] has been somewhat confusing as it did not meet with generally accepted norms for human cell differentiation molecules \[[@CR55]\]. While CD39 (now NTPDase1) indeed belongs to the cluster of differentiation antigens, CD39L1 (NTPDase2), CD39L3 (NTPDase3), CD39L4 (NTPDase5) and CD39L2 (NTPDase6) do not. Scientists at the Second International Workshop on Ecto-ATPases proposed that all E-NTPDase family members be termed as NTPDase proteins and classi-fied in order of discovery and characterization \[[@CR34], [@CR56]\]. The CD39 nomenclature should fall away for all but the prototypic member NTPDase1 that already has a long history of use in the Immunology and Oncology fields. Further revisions are however inevitable.

Catalytic properties {#Sec4}
====================

The individual NTPDase subtypes differ in cellular location and functional properties. The four cell surface-located forms (NTPDase1,2,3,8) can be differentiated according to substrate preference, divalent cation usage and product formation. All surfacelocated NTPDases require Ca^2+^ or Mg^2+^ ions in the millimolar range for maximal activity and are inactive in their absence \[[@CR34], [@CR57]\]. They all hydrolyze nucleoside triphosphates including the physiologically active ATP and UTP. Notably, the hydrolysis rates for nucleoside diphosphates vary considerably between subtypes (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Whereas NTPDase1 hydrolyzes ATP and ADP about equally well, NTPDase3 and NTPDase8 reveal a preference for ATP over ADP as substrate. NTPDase2 stands out for its high preference for nucleoside triphosphates and therefore has previously also been classified as an ecto-ATPase \[[@CR34], [@CR57]\]. In contrast to NTPDase1 and NTPDase2, murine NTPDase3 and NTPDase8 are preferentially activated by Ca^2+^ over Mg^2+^ \[[@CR52], [@CR58], [@CR59]\]. Presumably, differences in sequence but also in secondary, tertiary and quaternary structure account for differences between subtypes in the catalytic properties \[[@CR60], [@CR61]\]. Fig. 2Cell surface-located catabolism of extracellular nucleotides and potential activation of receptors for nucleotides (P2 receptors) and adenosine (P1 receptors). The *figure* depicts the principal catalytic properties of members of the E-NTPDase family and of ecto-5′-nucleotidase. NTPDases sequentially convert ATP to ADP + Pi and ADP to AMP + Pi. NTPDase1 is distinct among these enzymes as it dephosphorylates ATP directly to AMP without the release of significant amounts of ADP. Hydrolysis of the nucleoside monophosphate to the nucleoside is catalyzed by ecto-5′-nucleotidase. NTPDases, NPPs and alkaline phosphatase sometimes co-exist and it seems likely that they can act in concert to metabolize extracellular nucleotides. ATP can activate both P2X receptors and subtypes P2Y receptors whereas UTP activates subtypes of P2Y receptors only. After degradation, ADP or UDP may activate additional subtypes of P2Y receptors. The adenosine formed can potentially act on four different types of P1 receptors and is either deaminated to inosine or directly recycled *via* nucleoside transporters. *Bottom*: Profiles of nucleotide hydrolysis and substrate formation by plasma membrane-located NTPDases. The *figure* compares catalytic properties of human and murine NTPDase1,2,3 and 8, following expression in COS-7 cells. The principal catalytic properties of the respective human and murine enzymes are similar. ATP (•), ADP (▪), AMP (≆). Modified from \[[@CR57]\].

Membrane-bound NTPDase1 hydrolyzes ATP almost directly to AMP with the transient production of minor amounts of free ADP (Fig. [2](#Fig2){ref-type="fig"}). This functional property largely circumvents activation of P2Y-receptors for nucleoside diphosphates. Interestingly, significant amounts of UDP are accumulated when UTP is hydrolyzed by NTPDase1 \[[@CR57]\]. In contrast, ADP is released upon ATP hydrolysis by NTPDase2, then accumulates and is slowly dephosphorylated to AMP. On the one hand, this results in the removal of agonists for nucleoside triphosphate-sensitive P2Y-receptors (Fig. [2](#Fig2){ref-type="fig"}). On the other hand, it generates agonists for nucleoside diphosphate-sensitive receptors such as platelet P2Y~1~ and P2Y~12~ receptors \[[@CR62]\]. The actions of NTPDase3 and NTPDase8 result in intermediate patterns of product formation, leading to a transient accumulation of diphosphonucleosides with the simultaneous presence of triphosphonucleosides.

Principal structural features {#Sec5}
=============================

The hallmarks of all NTPDases are the five highly conserved sequence domains known as 'apyrase conserved regions', abbreviated and termed ACR1 to ACR5 \[[@CR42], [@CR63], [@CR64]\] that are involved in the catalytic cycle. This notion is supported by a considerable variety of deletion and mutation experiments \[for reviews see [@CR30], [@CR34], [@CR64]--[@CR68]\].

NTPDases share two common sequence motifs with members of the actin/HSP70/sugar kinase superfamily, the actin-HSP 70-hexokinase b-and g-phosphate binding motif \[(I/L/V)X(I/L/V/C)DXG(T/S/G)(T/S/G)XX(R/K/C)\] \[[@CR42], [@CR47], [@CR69], [@CR70]\], with the DXG sequence strictly conserved. These motifs are identified in ACR1 and ACR4. Furthermore, there are striking similarities in secondary structure with members of the actin/HSP70/sugar kinase superfamily \[[@CR30], [@CR59], [@CR71]\]. These proteins are soluble, have ATP phosphotransferase or hydrolase activity, depend on divalent metal ion and tend to form oligomeric structures. In spite of negligible global sequence identity they share the principal structure of two major domains (I and II, possibly resulting from gene duplication) of similar folds on either side of a large cleft. They reveal similar conserved secondary structure topology (β1β2β3α1β4α2β5α3) repeated in each domain and fold into a pocket for substrate binding at the bottom \[[@CR59]\]. Presumably, NTPDases share not only secondary structure but also major elements of tertiary structure with members of the actin/HSP70/sugar kinase superfamily (Fig. [3](#Fig3){ref-type="fig"}). Homology modeling of the NTPDase3 sequence reveals high degrees of structural fold similarity with a bacterial exopolyphosphatase (PDB 1T6C) that further refine structural predictions for members of the E-NTPDase family \[[@CR30], [@CR72]\]. Fig. 3Hypothetical membrane topology of a surface-located NTPDase with two transmembrane domains. A comparison of the conserved secondary structure reveals duplicate conservation of two major domains related to subdomains Ia and IIa of actin, and other members of the actin/HSP70/sugar kinase superfamily \[[@CR59]\]. In contrast to the other members of the superfamily, surface-located NTPDases are anchored to the plasma membrane by terminal hydrophobic domains. The figure takes into account the close distance of the N-and C-terminus of actin at domain I and the binding of ATP (red) in the cleft between domains I and II \[[@CR80]\]. These two domains are expected to undergo conformational changes involving movement relative to each other.

NTPDases readily form homo-oligomeric assemblies. NTPDase1 to NTPDase3 were found as dimers to tetramers \[[@CR29], [@CR64], [@CR73]--[@CR78]\]. In contrast to the P2X receptors that share a similar membrane topography, hetero-oligomeric complexes between NTPDases have not been reported, to date. Oligomeric forms reveal increased catalytic activity \[[@CR73], [@CR75], [@CR76]\] and the state of oligomerization can affect catalytic properties \[[@CR77], [@CR78]\].

NTPDase1,2,3, and 8 are firmly anchored to the membrane via two transmembrane domains that in the instance of NTPDase1 are important for maintaining catalytic activity and substrate specificity \[[@CR29], [@CR64], [@CR79]\]. The two transmembrane domains interact both within and between monomers. They may also undergo coordinated motions during the process of nucleotide binding and hydrolysis \[[@CR29], [@CR61]\]. This could in turn induce conformational changes \[[@CR80]\] involving movement of the two major domains (I and II) relative to each other (Fig. [3](#Fig3){ref-type="fig"}). Alterations in quarternary structure and subunit interactions may thus affect the impact or interaction of ACRs involved in substrate binding and hydrolysis. Whether posttranslational modifications such as protein phosphorylation contribute to this dynamic behavior remains to be investigated.

Functional modifications {#Sec6}
========================

Biologically active NTPDase1 is subject to differential forms of surface modification under conditions of oxidative stress that inhibit enzymatic activity, as influenced by unsaturated fatty acids \[[@CR81], [@CR82]\]. It also undergoes limited proteolysis that increases enzyme activity and differential glycosylation reactions that appear to be required for membrane expression \[[@CR64]\]. Since the surface-located ATP-hydrolyzing members of the NTPDase family pass through the endoplasmic reticulum and Golgi apparatus, the associated catalytic activity might abrogate ATP-dependent luminal functional processes. NTPDase1 becomes catalytically active on reaching the cell surface and glycosylation reactions appear crucial in this respect \[[@CR83]\].

The N-terminal intracytoplasmic domain of NTPDase1 is palmitoylated. Truncated forms of NTPDase1 lacking the N-terminal intracytoplasmic region and the associated Cys~13~ residue, are not subject to palmitoylation. This post-translational modification appears to be constitutive and to contribute to the integral membrane association of this ectonucleotidase in lipid rafts \[[@CR84]--[@CR86]\]. This raises the possibility that NTPDase1 may be recycled to and from cell membranes via sequential actions of putative palmitoyltransferases and palmitoyl-protein thioesterases \[[@CR87]\], in order to fine tune and modulate purinergic signaling responses. In contrast to NTPDase1 and NTPDase3, NTPDase2 does not have the required intra-cytoplasmic Cys to undergo this post-translational modification. The potential multimerization of NTPDase1 \[[@CR35]\] may be facilitated by acylation with intermolecular interactions within the cholesterol and sphingolipid-rich microdomains of the plasma membrane \[[@CR88]\]. Experiments using endothelial cells from caveolin-1 deficient mice suggest that caveolae are not essential for the enzymatic activity or for the targeting to the plasma membrane of NTPDase1. However, cholesterol depletion results in a strong inhibition of the enzyme \[[@CR86]\]. The targeting of palmitoylated NTPDase1 to lipid rafts could influence defined G-protein coupled receptors within this plasmalemmal microenvironment and thus regulate cellular signal transduction pathways. Furthermore, the caveolar co-localization of ecto-5′-nucleotidase, P2 receptors, and NTPDase1 could serve to modulate signaling via both ATP and adenosine at the cell surface and possibly also within endosomal compartments \[[@CR20]\].

Transcriptional regulation of expression {#Sec7}
========================================

Members of the E-NTPDase family are constitutively expressed in many tissues. To date, there is only scattered evidence on promoters and the factors controlling NTPDase expression \[[@CR22]\]. The transcription of NTPDase1/CD39 is constitutive in venous, arterial and certain non-fenestrated microvascular endothelium and certain immune cells e.g., B cells, dendritic cells and defined T-cell subsets \[[@CR20], [@CR89]\]. The modulated expression of NTPDase1 has been closely associated with inflammatory cytokines, oxidative stress and hypoxia *in vitro* and *in vivo* \[[@CR19], [@CR90]\].

Expression of NTPDase1 is increased in differentiating melanomas followed by a gradual decrease with tumor progression \[[@CR91]\] and enhanced NTPDase1 activity of stimulated endothelial and mesangial cells is downregulated by glucocorticosteroids \[[@CR92]\]. Activity of 'ecto-ATP diphosphohydrolase' in human endothelial cells *in-vitro* is increased by aspirin \[[@CR93]\] and glomerular 'ecto-ATP diphosphohydrolase' immunoreactivity might well be modulated by estradiol \[[@CR94]\].

Transcription of NTPDase2 in mouse hepatoma cells is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) \[[@CR95]\]. These cells contain both constitutive and TCDD-inducible NTPDase2 activity. The NTPDase2 core promotor reveals constitutive activity that is independent of TCDD \[[@CR96]\]. TCDD does not increase expression of NTPDase1, NTPDase3 or other ectonucleotidases and apparently fails to induce NTPDase2 in a variety of other cell lines derived from varying species \[[@CR97]\]. In rat Sertoli cells, NTPDase2 is upregulated by follicle-stimulating hormone and cAMP \[[@CR98]\] and it is selectively downregulated in biliary cirrhosis \[[@CR99]\]. Human epidermoid carcinoma cells increase the cascade for extracellular nucleotide hydrolysis when periodically treated with extracellular ATP, suggesting that the substrate itself may affect the expression of its own hydrolysis chain \[[@CR100]\].

Inhibitors {#Sec8}
==========

A considerable number of compounds alter and inhibit extracellular nucleotide hydrolysis by NTPDases. These include non-hydrolysable nucleotide analogues and inhibitors of P2 receptors. Ideally, NTPDase inhibitors should not be P2 receptor agonists or antagonists and not be subject to dephosphorylation by the ectoenzyme \[[@CR22], [@CR101], [@CR102]\]. The only commercially available compound reported to effectively inhibit hydrolysis of ATP in a variety of tissues without significantly acting on purinoceptors is the structural analogue of ATP, ARL 67156 (FPL 67156) (6-*N*, *N*-diethyl-D-β,γ-dibromomethylene ATP) \[[@CR103]--[@CR105]\]. Other potential inhibitors include 8-thiobutyladenosine 5′-triphosphate (8-BuS-ATP) \[[@CR106]\] and 1-naphthol-3, 6-disulfonic acid (BG0136) \[[@CR101]\]. Periodate-oxidized ATP inhibits ecto-ATPase activity in 1312N1 human astrocytoma cells \[[@CR107]\] and Gadolinium ions have been found to effectively inhibit the ecto-nucleoside triphosphate diphosphohydrolase from *Torpedo* electric organ as well as potato apyrase \[[@CR108]\].

It is noteworthy that the potency of inhibitors can vary considerably between individual members of the E-NTPDase family \[[@CR109]--[@CR111]\]. This necessitates a functional evaluation of each inhibitor for the enzyme investigated in a given tissue or cell type. The failure to develop specific inhibitors remains a major impediment to ongoing discoveries.

Principal functional contexts {#Sec9}
=============================

Cell surface-located NTPDases are considered to be of major importance for controlling the availability of extracellular nucleotide agonists at P2 receptors. They also contribute to recycling of nucleosides derived from extracellular nucleoside phosphates and metabolic salvage pathways. The number of studies that define a functional impact of individual NTPDases in purinergic signaling *in situ* is limited and has been dependent to date on global genetic modifications of mice and swine to delete or upregulate the NTPDase or P2 gene of interest \[[@CR20]\]. Subtype-specific inhibitors, siRNA approaches, and animals in which the encoding gene can be inactivated or selectively induced in specific tissues will be of major importance.

There is increasing experimental evidence that ectonucleotidases compete with P2 receptors for a limited pool of endogenously released nucleotide \[[@CR112], [@CR113]\] and ---by hydrolyzing released nucleotide ---terminate or modulate the function of P2 receptors \[[@CR114]--[@CR116]\]. Portal fibroblasts regulate P2Y receptormediated bile duct epithelial proliferation via expression of NTPDase2 \[[@CR117]\] (see liver section, below). NTPDases functionally interact with P2Y-receptors \[[@CR112]\] and may also co-localize with these G-proteincoupled receptors (GPCR) in lipid rafts and possibly caveolae \[[@CR118]--[@CR121]\]. The modulatory effects of NTPDases are complex as the enzymes differentially regulate agonist availability in a process that is dependent upon P2 receptor subtype by either degrading ATP/UTP or by generating ADP/UDP (Fig. [2](#Fig2){ref-type="fig"}).

Recent experiments suggest that plasma membranebound NTPDases may have functions distinct from their catalytic properties alone. In a yeast two-hybrid system using techniques developed by Zhong for yeast apyrases \[[@CR122]\], the N-terminus of human NTPDase1 (used as bait protein) has been shown to interact with truncated Ran Binding Protein M (RanBPM, otherwise known as RanBP9, NM_005493) in the human library screened \[[@CR122]\]. RanBPM contains conserved SPRY (repeats in [splA]{.ul} and [RyR]{.ul}) domains that appear to be crucial for the interaction with NTPDase1 and is preferentially distributed in human heart tissues \[[@CR123]\]. RanBPM is known to interact with Sos and regulate ERK/Ras signaling. NTPDase1 interacts with RanBPM to directly modulate Ras activation and cellular proliferation in liver regeneration following partial hepatectomy \[[@CR124]\].

The N-termini of NTPDases also have consensus sequences for protein phosphorylation by protein kinase C \[[@CR47]\] that could have additional functional impacts. Furthermore, the C-terminal sequence of NTPDase1 contains a putative PDZ domain (-K-DM-V). This may have utility in determining interactions with select P2Y receptors e.g., the purinergic P2Y~1~ and P2Y~2~ receptors that terminate in -D-T-S-L and -D-I-R-L, respectively \[[@CR125]\]. PDZ domains are most often found in combination with other protein interaction domains (for instance, SH3, PTB, WW), participating in complexes that facilitate signaling or determine the localization of receptors \[[@CR126]--[@CR128]\].

Finally, the general membrane topography of NTPDase1 and oligomeric assembly resemble the morphology of channel forming proteins such as P2X nucleotide receptors and members of the epithelial Na^+^ channel/degenerin gene superfamily \[[@CR129]\]. This raises the question whether, in addition to their catalytic activity, NTPDases could function as channels. Release of ATP from *Xenopus* oocytes induced by hyperpolarizing pulses requires functional ecto-ATPase activity \[[@CR130]\]. To what extent this functional property is shared by the structurally related NTPDase2, NTPDase3 and NTPDase8 has not been investigated.

Vasculature {#Sec10}
===========

The normal vascular endothelium provides a barrier that separates blood cells and plasma factors from highly reactive elements of the deeper layer of vessel wall. The vessel wall maintains blood fluidity and promotes flow by inhibiting coagulation, platelet activation and promoting fibrinolysis \[[@CR131]\]. These properties are governed by important thromboregulatory mechanisms; key biological activities of the vasculature have been already identified and shown to be ecto-nucleotide catalysts that generate the respective nucleosides by phosphohydrolysis \[[@CR19], [@CR82]\]. The dominant ectonucleotidases of the vasculature have now more fully been characterized as NTPDases. This important biological property expressed by the endothelium and associated cells is responsible for the regulation of extracellular and plasma levels of nucleotides \[[@CR20], [@CR44], [@CR82], [@CR132], [@CR133]\].

Over the past decade, extracellular nucleotides have been recognized as important mediators of a variety of processes including vascular inflammation and thrombosis with varying impacts in different systems \[[@CR19]\]. Adenosine and ATP mediated effects or mechanisms can be implicated in the local control of vessel tone as well as in individual vascular cell migration, proliferation and differentiation. As an example, ATP may be released from sympathetic nerves (see later sections) and results in constriction of vascular smooth muscle through effects mediated by P2X receptors. In contrast, ATP released from endothelial cells during changes in flow (shear stress) or following exposure to hypoxic conditions activates P2Y receptors in a paracrine manner to release NO, resulting in vessel relaxation. Any nucleotide released will be ultimately hydrolyzed to adenosine and will result in vasodilatation via the effects of smooth muscle P1 receptors. P2X receptors also appear on vascular cells and are associated with changes in cell adhesion and permeability \[[@CR2]\]. These cellular processes and nucleotidetriggered events are modulated during angiogenesis (Fig. [4](#Fig4){ref-type="fig"}) and influence the development of atherosclerosis and restenosis following angioplasty \[[@CR2], [@CR113], [@CR134]--[@CR136]\]. Fig. 4Angiogenesis with expression of NTPDase1 in the vasculature of syngeneic islet transplants. Mouse islets were prepared from wild type and *Entpd1* null mice, as described by T. Maki et al. and transplanted under the renal capsule \[[@CR261]\]. Islets were harvested at four weeks (*n* = 4 per group) and stained for NTPDase1 immunoactivity and other markers of EC. Substantially diminished levels of CD31 staining vascular elements were also present in null to *Entpd1* null grafts, indicating a defect in new vessel growth (not depicted here). A) Wild type to wild type showing grafted islet vasculature staining for NTPDase1 with adjacent normal renal vascular pattern. B) Wild type to null mouse showing intrinsic vasculature of islet has persisted within the graft and even entered the NTPDase1 null renal parenchyma. C) Null to wild type grafts showing infiltrating macrophages and NTPDase1 positive endothelium migrating from recipient (confirmed by other stains; not shown).

NTPDase1 is the major ectonucleotidase in the vasculature \[[@CR112]\]. Other NTPDases associated with the vasculature are the cell-associated NTPDase2 and the soluble monocyte expressed NTPDase5 \[[@CR32], [@CR50], [@CR137]\]. The phosphohydrolytic reaction of NTPDase1 limits the platelet activation response that is dependent upon the paracrine release of ADP and activation of specific purinergic receptors \[[@CR81], [@CR132], [@CR138]\]. In contrast, NTPDase2, a preferential nucleoside triphosphatase, activates platelets by converting the competitive antagonist (ATP) of platelet ADP-receptors to the specific agonist of the P2Y~1~, and P2Y~12~ receptors. In keeping with these biochemical properties, NTPDase1 is dominantly expressed by endothelial cells and the associated vascular smooth muscle where it serves as a thromboregulatory factor. In contrast, NTPDase2 is associated with the adventitial surfaces of the muscularized vessels, microvascular pericytes of some tissues and organs as the heart and the stromal cells and would potentially serve as a hemostatic factor \[[@CR62]\].

Extracellular nucleotide stimulation of P2 receptors represents components of platelet, endothelial cell and leukocyte activation that culminate in vascular thrombosis and inflammation *in vivo* \[[@CR19]\]. In these inflammatory settings, with oxidant endothelial injury, NTPDase1 biochemical function is substantially, albeit temporarily, decreased because of post-translational changes; reconstitution of vascular NTPDase activity occurs following transcriptional upregulation of CD39 in endothelium \[[@CR82], [@CR139]\]. This functional change may relate, at least in part, to alterations in acylation and associated membrane lipid association with consequent disruption of multimer structure. Interestingly, palmitate supplementation may protect against loss of NTPDase activity following cellular activation *in vitro* \[[@CR81]\]. These observations may provide several avenues of research to augment NTPDase activity within the vasculature at sites of injury \[[@CR134]\].

Mechanisms of endothelial cell activation by nucleotides {#Sec11}
--------------------------------------------------------

ATP and UTP increases intracellular calcium levels, results in cytoskeletal rearrangements and stimulates phosphorylation of several proteins in human endothelial cells (EC) that are also associated with integrin signaling \[[@CR140]--[@CR142]\]. These include the focal adhesion kinase (FAK) and paxillin, proline-rich tyrosine kinase 2 (Pyk2) (also named related adhesion focal tyrosine kinase, RAFTK) and p38 MAP kinase. Further, UTP preferentially increases EC migration in a PI3-kinase and ERK-dependent manner. Moreover, extracellular nucleotide-mediated EC activation involves cytoskeletal rearrangements and increases in cell motility, comparable to that seen with ligation of integrins by extracellular matrix proteins \[[@CR143]\]. These phenotypic changes (seen in both nucleotide-and matrix-mediated activation) are associated with tyrosine phosphorylation of FAK, paxillin and p130 Crk-associated substrate (p130^cas^) and down-stream activation of p38 MAP kinases. FAK has been implicated to play an important role in integrin-mediated signal transduction pathways \[[@CR144]\], suggesting that P2-receptors are implicated in 'inside-out' integrin signaling in EC, as well as platelets \[[@CR20], [@CR112]\].

Therapeutic considerations {#Sec12}
--------------------------

To test how extracellular nucleotide-mediated signaling influences pathophysiological events, several techniques have been developed and validated to manipulate NTPDase1 expression in the vasculature and to study conditions of inflammatory stress. The first mutant mouse derived and studied concerned the global deletion of the gene encoding the dominant ectonucleotidase NTPDase1 (*Entpd1,cd39*). The mutant mice exhibit major perturbations of P2 receptormediated signaling in the vasculature and immune systems \[[@CR19], [@CR89], [@CR145]\]. These phenomena manifest as hemostatic defects, thromboregulatory disturbances, heightened acute inflammatory responses with a failure to generate cellular immune responses that are all associated with vascular endothelium, monocyte, dendritic cell and platelet integrin dysfunction \[[@CR20], [@CR112], [@CR134]\].

The therapeutic potential of NTPDase1 to regulate P2 receptor function in the vasculature and mitigate against thrombotic/inflammatory stress has been further established by the generation of NTPDase1 transgenic mice and swine \[[@CR20], [@CR146]\], the use of adenoviral vectors to upregulate NTPDase1 in cardiac grafts \[[@CR147]\] and the use of soluble derivatives of NTPDase1 and apyrases \[[@CR133], [@CR148]\]. The beneficial effects of administered NTPDases have been determined in several animal models of vascular inflammation \[[@CR148], [@CR149]\]. Exogenous infusions of soluble NTPDases are able to rescue *Entpd1*-deficient mice from systemic toxicity induced by ischemia reperfusion injury and after stroke induction \[[@CR145], [@CR150]\].

Angiogenesis requires the dynamic interaction of endothelial cell proliferation and differentiation with orchestrated interactions between extracellular matrix and surrounding cells (such as vascular smooth muscle and/or pericytes) \[[@CR151]--[@CR153]\]. NTPDase1 appears crucial in the co-ordination of angiogenic responses in inflammation, organ remodeling and transplantation \[[@CR20], [@CR134]\]. For example, in syngeneic pancreatic islet transplantation, the maintenance and revascularization of grafted islets appears dependent upon expression of NTPDase1 by the developing vasculature within the islet (Fig. [4](#Fig4){ref-type="fig"}).

In summary, multiple experimental studies largely reveal beneficial effects of over-expression of NTPDases within the vasculature, or by their pharmacological administration \[[@CR20], [@CR133]\]. Clinical studies of these soluble thromboregulatory factors are in planning \[[@CR20], [@CR154], [@CR155]\].

Immune system {#Sec13}
=============

There are multiple P2X and P2Y receptor subtypes expressed by monocytes and dendritic cells, whereas lymphocytes express only P2Y receptors \[[@CR2]\]. NTPDase1/CD39 was first described as a B lymphocyte activation marker and also shown to be expressed on activated T cells \[[@CR156], [@CR157]\] and dendritic cells \[[@CR89]\]. The CD39 enzymatic function on dendritic cells is involved in the recruitment, activation and polarization of naive T cells. ATP is released by CD4^+^ and CD8^+^ T cells upon stimulation with Con A or anti-CD3 mAb while CD39 functions as an additional recognition structure on haptenated target immunocytes for HLA-A1-restricted, hapten-specific cytotoxic T cells \[[@CR156], [@CR157]\].

In *cd39* null mice, there are major defects in dendritic cell function antigen presentation and T-cell responses to haptens (type IV hypersensitivity reactions) \[[@CR19], [@CR89]\]. Immunocyte-associated CD39 may play an immunoregulatory role by hydrolyzing ATP (and perhaps ADP) released by T cells during antigen presentation and thereby generating adenosine \[[@CR19], [@CR89], [@CR158]\]. Ectoenzymes, including ectonucleotidases, are known to play an important role in leukocyte trafficking (for an excellent review on this topic, see \[[@CR159]\]).

Recent work has indicated that regulatory CD4 + ve CD25 + ve T cells (T~reg~ cells) play important roles in the maintenance of immunological reactivity and tolerance \[[@CR160]\]. The selective expression of CD39 by T~reg~ and the question whether this ectonucleotidase and/or extracellular nucleotides influence(s) the function of these interesting cells is a focus of current work.

Digestive and renal systems {#Sec14}
===========================

Released nucleotides are polarized and do not re-enter cells. They have to be transformed into the corresponding nucleosides that enter cells via specific transporters to rebuild nucleoside pools. If this did not occur, they would be lost from the metabolic pool. The same may pertain to dietary ingestion of nucleotides where NTPDases are potential participants in the digestion of exogenous nucleotides and intestinal function. In addition, extracellular nucleotide and adenosine receptors are highly expressed in the digestive and renal systems, so these molecules are likely to have homeostatic functions \[[@CR2]\].

An important nucleotide-mediated mechanism that seems common to various epithelia, as well as to hepatocytes, involves the autocrine regulation of cell volume by ATP via P2 receptors \[[@CR161], [@CR162]\]. As P2 receptors are expressed by epithelia in a polarized manner and can be linked to several digestive and homeostatic functions \[[@CR163], [@CR164]\], the presence of NTPDases in the immediate environment may serve as regulatory switches.

Liver {#Sec15}
-----

In the liver, extracellular nucleotides are potentially involved in several functional contexts \[[@CR161]\]. There is evidence that extracellular nucleotides regulate glycogenolysis through activation of glycogen phosphorylase and inactivation of glycogen synthase by inhibition of the glucagon effect on cAMP and by the activation of phospholipase D \[[@CR165], [@CR166]\]. In addition, nucleotides may be involved in the regulation of canalicular contraction and bile flow \[[@CR167]--[@CR169]\]. Concentrations of canalicular adenine nucleotides in bile samples and effluents from hepatic cell lines are estimated to be around 0.1 to 5 µM \[[@CR161], [@CR168]\]. Hepatocytes and bile duct cells have been shown to interact and communicate via local ATP release *in vitro* \[[@CR170]\]. Extracellular ATP acts as a hepatic mitogen and activates JNK signaling and hepatocyte proliferation both *in vitro* and *in vivo* \[[@CR171]\].

Several ectonucleotidases are expressed in liver. Of the nucleotide pyrophosphatase/phosphodiesterases, NPP1 (PC-1) is expressed on the basolateral membrane of hepatocytes while the closely related NPP3 (B10) has a predominant canalicular in distribution \[[@CR172], [@CR173]\]. NTPDase1 is highly expressed on larger vessels and more weakly on sinusoids as well as in Kupffer cells \[[@CR174]\]. In the quiescent liver, NTPDase2 is expressed by cells of the subendothelium of veins and adventitial cells of arteries, but not in sinusoids. In addition, NTPDase2 is expressed by portal fibroblasts near basolateral membranes of bile duct epithelia \[[@CR175]\]. Activated but not quiescent hepatic stellate cells express NTPDase2 at the protein level \[[@CR176]\]. Only low expression of NTPDase3 could be demonstrated at the mRNA level in the liver \[[@CR50], [@CR177]\].

NTPDase2 expression in portal fibroblasts, the primary fibroblastic cell type of the portal area, suggests a role in the regulation of bile ductular signaling and secretion \[[@CR161], [@CR175]\]. Jhandier et al. tested the hypothesis that portal fibroblast NTPDase2 regulates epithelial cell proliferation. Using co-cultures of cholangiocytes (Mz-ChA-1 human cholangiocarcinoma cells) and primary portal fibroblasts from rat liver, increased NTPDase2 expression decreased cell proliferation, and knockdown of NTPDase2 by siRNA increased proliferation. P2 receptor blockade also attenuated Mz-ChA-1 proliferation \[[@CR117]\]. These experiments defined a novel cross-talk signaling pathway between bile duct epithelial cells and underlying portal fibroblasts, regulated by NTPDase2. Because they are the chief fibrogenic cells of the liver, hepatic stellate cells and portal fibroblasts are important targets of liver disease therapy. Loss of NTPDase2 expression in human biliary cirrhosis, as well as in models of bile duct ligation in rat, has been observed. NTPDase2 expression also shifts from the portal area to bridging fibrous bands in cirrhosis with hepatitis C \[[@CR99]\].

Functional ATPases were previously shown to be associated with bile canalicular plasma membranes by histochemical techniques \[[@CR178]\]; the corresponding enzyme was subsequently incorrectly identified as cCAM105 \[[@CR179]--[@CR181]\]. More recent studies revealed that the canalicular ecto-ATPase corresponds to NTPDase8 \[[@CR52]\], also referred to as hepatic ATP diphosphohydrolase (ATPDase) \[[@CR174], [@CR182]\]. NTPDase8 is the mammalian orthologue of the chicken ecto-ATPDase cloned from oviduct and liver \[[@CR183], [@CR184]\]. In tandem with ecto-5′-nucleotidase, NTPDase8 has the potential to regulate the concentration of nucleotides in the hepatic canalicule. The ultimate generation of extracellular adenosine from dephosphorylated ATP not only activates adenosine receptors but also produces the key molecule for purine salvage and consequent replenishment of ATP stores within many cell types \[[@CR17], [@CR185]\]. Adenosine transporters are of major importance to organs and cells incapable of de novo nucleotide synthesis such as brain, muscle, intestinal mucosa and bone marrow \[[@CR167], [@CR186]\]. As the liver appears to be a major source of purines for these tissues, curtailment of nucleotide loss into the bile may be important to maintain appropriate nucleotide/nucleoside concentrations within hepatocytes \[[@CR185]\]. Thus, dephosphorylation of nucleotides by ectonucleotidases may be critical for appropriate systemic purine homeostasis \[[@CR167]\]. The presence of NTPDase8, ecto-5′-nucleotidase and nucleoside transporters in the canalicular domain of hepatocytes would be consistent with an important role of NTPDase8 in purine salvage.

The exocrine pancreas {#Sec16}
---------------------

The exocrine pancreas secretes digestive enzymes and a HCO~3~-rich fluid. Acini release ATP and the excurrent ducts express several types of P2 receptors \[[@CR187], [@CR188]\]. Thus ATP may function as a paracrine mediator between pancreatic acini and ducts. Ectonucleotidase activity in pancreatic tissues was first detected in the rat in the 1960s \[[@CR189], [@CR190]\], followed by analyses in the pig \[[@CR191], [@CR192]\]. Cytochemical and biochemical observations have corroborated the association of ATPase activity with zymogen granules \[[@CR193]\]. In other studies of small intercalated/interlobular ducts, NTPDase1 immuno-fluorescence can be localized on the luminal membranes, while in larger ducts it is localized on the basolateral membranes \[[@CR194]\]. Upon stimulation with cholecystokinin octapeptide-8 (CCK-8), acinar NTPDase1 relocalized in clusters towards the lumen and is secreted into the pancreatic juice, as an active form associated with particulate fractions \[[@CR188], [@CR195]\]. As revealed by electron microscopy, NTPDase2 is located on epithelial cells, myoepithelial cells and the basolateral membrane of acini. Interestingly, NTPDase2 could be also detected at the basolateral surface of endothelial cells \[[@CR194]\].

Salivary glands {#Sec17}
---------------

There are only few studies on the localization of NTPDases in salivary glands. NTPDases might play a role in the transport of electrolytes by modulating the extracellular ATP concentration in the salivary gland ducts. NTPDase1 reveals to be mainly vascular in expression. NTPDase2 was immunodetected on myoepithelial cells and in nerves \[[@CR194], [@CR196]\]. The immunolocalization of NTPDases 3 and 8 in salivary glands has not yet been determined.

Kidney {#Sec18}
------

The kidney reveals a complex cellular profile of expression for P1 and P2 receptors as well as of ectonucleotidases. Both ATP and adenosine have been invoked in the regulation of tubuloglomerular feedback \[[@CR197], [@CR198]\]. This feedback system links the salt concentrations in the tubular fluid at the macula densa to the vascular tone of the afferent arteriole of the same nephron. As depicted by their localization, NTPDases may participate in the regulation of several biological functions of the kidney, including vascular perfusion. In mouse, rat and porcine kidneys, NTPDase1 can be detected in vascular structures, including blood vessels of glomerular and peritubular capillaries \[[@CR174], [@CR199], [@CR200]\]. NTPDase2 is detected on the Bowman's capsules of mouse and rat \[[@CR199]\] and NTPDase8 on the luminal side of porcine renal tubules \[[@CR174]\]. More recently, an immunohistochemical analysis of various ectonucleotidases of the rat nephron revealed expression of both NTPDase2 and NTPDase3 in the thick ascending limb, the distal tubule and the inner medullary collecting ducts. In addition, NTPDase3 is located in the cortical and outer medullary collecting ducts \[[@CR201]\].

The nervous system {#Sec19}
==================

All cell types of the nervous system express nucleotide receptors \[[@CR2]\]. It is increasingly apparent that NTPDases are distributed in the nervous system as ubiquitously as are P2 receptors and that these ectoenzymes are directly involved in the control of P2 receptor function in nervous tissues \[[@CR22], [@CR31], [@CR36]\]. Signaling via nucleotides is widespread both in the peripheral and central nervous system. Major nucleotide receptormediated functions in the central nervous system include the modulation of synaptic signal transmission \[[@CR202]\], the propagation of Ca^2+^ waves between glial cells \[[@CR203]\], or the control and activation of astrocytes and microglia \[[@CR204], [@CR205]\]. In addition, ATP can contribute to synaptic signal transmission \[[@CR36]\]. In the sympathetic nervous system, ATP acts as a fast neurotransmitter together with catecholamines \[[@CR206]\], it is an important mediator of central and peripheral chemosensory transduction, including pain \[[@CR207]\] and it is involved in the control of myelination formation of peripheral axons \[[@CR208]\].

Central nervous system {#Sec20}
======================

ATP can be rapidly hydrolyzed to adenosine at brain synapses that in turn activates pre-or postsynaptic receptors, thereby modulating neuronal transmission. Adenine nucleotides undergo conversion to adenosine within a few hundred milliseconds in the extracellular (synaptic) space of rat brain slices \[[@CR209], [@CR210]\]. Complex synaptic interactions in the central nervous system may thus be modulated both by the activation of P2 and (after hydrolysis of the nucleotide) P1 receptors that may be located at identical or different cellular targets \[[@CR202], [@CR211]\].

Based on immunoblotting and *in situ* hybridization, NTPDase1, 2 and 3 are expressed in the mammalian brain \[[@CR47], [@CR57], [@CR59], [@CR116], [@CR177], [@CR212]\]. NTPDase1 and 2 have been purified from porcine brain \[[@CR213], [@CR214]\]. But the exact cellular allocation of individual subtypes is still a challenge. There is ample evidence from early enzyme histochemical investigations that surface-located catalytic activity for the hydrolysis of nucleoside tri-and diphosphates can be allocated to all cell types of the nervous system \[for reviews see [@CR22], [@CR31], [@CR36], [@CR215]\]. This catalytic activity can be localized to synapses, including the synaptic cleft, at the surface of neurosecretory nerve terminals in the pituitary or at peripheral nerve terminals. These data imply a wide distribution of cell surface-located ATP hydrolyzing activity in the CNS.

Neurons {#Sec21}
-------

Ecto-ATPase activity has been observed in synaptosomal fractions isolated from various sources, implying endogenous ectonucleotidase activity of nerve cells. Biochemical studies on isolated synaptosomes permit the determination of the ratios of ATP to ADP hydrolysis rates as well as the analysis of product formation. Total synaptosome fractions isolated from rat brain cortex and immunopurified cholinergic striatal synaptosomes revealed ratios of 3.4: 1 and 2.1: 1, respectively \[[@CR216]\]. ADP was found to transiently accumulate after addition of ATP, and was subsequently metabolized to AMP and adenosine. Similar results were obtained with hippocampal synaptosomes \[[@CR217]\]. This strongly argues against a major contribution by NTPDase1 and NTPDase2 and would rather be compatible with a neuronal expression of NTPDase3 (comp. Fig. [2](#Fig2){ref-type="fig"}). A recent immunocytochemical study allocates NTPDase3 to neurons including axon-like structures of various brain regions \[[@CR218]\].

Astrocytes, oligodendrocytes, and microglia {#Sec22}
-------------------------------------------

The ratio of ATP to ADP hydrolysis is clearly different in cultured astrocytes. Astrocytes cultured from cortex or hippocampus display a ratio of 8: 1 \[[@CR219]\]. Furthermore, cultured rat cortical astrocytes accumulate ADP from ATP that is only very slowly further degraded to AMP \[[@CR220]\]. This would be largely compatible with NTPDase2 as the major ectonucleotidase of cultured astrocytes. Immunocytological investigations of adult rat and mouse brain sections assign NTPDase2 solely to the astrocyte-like stem cells in the subventricular zone of the lateral ventricles and the dentate gyrus of the hippocampus and to astrocytes in few distinct additional brain regions \[[@CR221], [@CR222]\]. Thus, cultured astrocytes may reveal functional properties that differ from the *in situ* situation as they tend to rapidly alter their protein expression profile \[[@CR223]\].

Enzyme histochemistry assigns ecto-ATPase activity to both central and peripheral myelin \[[@CR31]\], but fully supplementary immunocytochemical data are lacking. Enzyme histochemical staining for surface-located nucleoside diphosphate activity has long been used to identify microglia in tissue sections of the adult and developing brain \[[@CR224]\]. The major microglial ectonucleotidase has been identified as NTPDase1 \[[@CR225]\].

Stem cells in the adult mammalian brain {#Sec23}
---------------------------------------

In the adult rodent brain, neurogenesis persists in two restricted regions, the subventricular zone (SVZ) of the lateral ventricles and the dentate gyrus of the hippocampus. These regions contain stem cells that give rise to neurons throughout the life span of the animal. Interestingly, these cells share astrocytic properties \[[@CR226]\]. They generate highly proliferating intermediate cell types and finally mature neurons. NTPDase2 is highly and selectively expressed by the stem cells (type B cells) of the SVZ \[[@CR221]\] (Fig. [5](#Fig5){ref-type="fig"}) as well as by the progenitor cells (residual radial glia) of the dentate gyrus \[[@CR222]\]. In the presence of epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2), SVZ-derived stem cells can be cultured as free floating cellular aggregates (neurospheres). Cultured stem cells express NTPDase2 and functional P2 receptors. Agonists of P2Y~1~ and P2Y~2~ receptors augment cell proliferation, whereas inhibition of the receptors attenuates cell proliferation in spite of the presence of mitogenic growth factors \[[@CR227]\]. These data suggest that NTPDase2 and nucleotides, together with other signaling pathways, contribute to the control of neurogenesis in the adult mammalian brain. Fig. 5Detail of arrangement of neuronal stem cells and neuroblasts at the lateral lining of the mouse subventricular zone (*SVZ*) (*triple labeling*). **A**) DAPI staining of all nuclei. *Arrow heads* mark endymal lining. **B**) Stem cells (type B cells) immunopositive for NTPDase2 form tube-like sheeths around clusters of migrating immature neurons (type A cells) that immunostain for the microtubule-associated protein doublecortin (DCX) (C). The spaces covered by type A cells remain dark in (**B**) and are indicated with *stars*. **D**) Merge of **B**) and C). **E**) Merge of A), B) and C). *[Bar]{.ul}* = 10 µm. (by courtesy of David Langer, Frankfurt am Main).

Apparently, individual enzyme isoforms govern cell surface-located nucleotide hydrolysis in the various cell types of the central nervous system. This does not exclude however, the possibility that individual cell types express more than one isoform with one of the enzymes predominating. For example, PC12 cells express mRNA for NTPDase1-3. But the ATP/ADP hydrolysis ratio, the pattern of product formation and the immunocytochemical surface staining suggest that NTPDase3 is the major functional isoform \[[@CR59], [@CR228]\]. Similarly cultured normal and immortalized pituitary and hypothalamic cells express NTPDase1-3 \[[@CR116]\]. The future planned use of transgenic mice expressing fluorescent protein under the promoter of the respective NTPDase isoform will greatly facilitate the identification of the expression pattern of individual enzyme isoforms in the developing and adult nervous system.

Peripheral nervous system {#Sec24}
=========================

Noradrenaline and ATP are co-released from sympathetic nerve terminals of the guinea pig heart whereby ATP enhances noradrenaline release by a mechanism controlled by ectonucleotidases, possibly NTPDase1 \[[@CR229]\]. Interestingly, stimulated sympathetic nerves of the guinea pig vas deferens release not only ATP and noradrenaline but also enzyme activity that degrades ATP to adenosine. The latter exhibits similarities to NTPDases and ecto-5′-nucleotidase but their molecular identity has not been defined \[[@CR230]\].

NTPDase2 associates with immature and non-myelinating Schwann cells of peripheral nerves whereas NTPDase1 immunoreactivity is absent \[[@CR231]\]. NTPDase2 is also expressed by the satellite glial cells in dorsal root ganglia and sympathetic ganglia and by the enteric glia surrounding cell bodies of ganglionic neurons of the myenteric and submucous plexus \[[@CR231]\].

Sensory systems {#Sec25}
===============

The most comprehensive investigation of expression of NTPDases within sensory systems concerns the inner ear. Ectonucleotidase activity is associated with the tissues lining the perilymphatic compartment of the cochlea \[[@CR232], [@CR233]\]. Immunohistochemical analysis of the murine cochlea has assigned NTPDase1 to the cochlear vasculature and primary auditory neurons in the spiral ganglion, whereas NTPDase2 is associated with synaptic regions of the sensory inner and outer hair cells, supporting cells of the organ of Corti and additional tissue elements \[[@CR234], [@CR235]\]. Interestingly, noise exposure induces upregulation of NTPDase1 and NTPDase2 in the rat cochlea \[[@CR236]\].

Taste buds transduce chemical signals in the mouth into neural messages. Taste cells and nerve fibers express P2X~2~ and P2X~3~ receptors \[[@CR237]\] and various P2Y receptors \[[@CR238], [@CR239]\]. Genetic elimination of P2X~2~ and P2X~3~ receptors revealed that ATP is a key neurotransmitter in this system \[[@CR240]\]. NTPDase2 is expressed at the mRNA level in mouse taste papillae \[[@CR241]\]. Immunohistochemistry and enzyme histochemical staining allocate NTPDase2 to type I 'glial-like' cells in the tongue, palate and larynx. Furthermore, NTPDase2 immunostaining is associated with nearby nerves, suggestive of Schwann cells, implying that NTPDase2 may be a regulator in defined taste transmission.

Pathological implications {#Sec26}
=========================

Cerebral ischemia {#Sec27}
-----------------

The interruption of blood flow accompanied by an interrupted supply of oxygen and glucose initiates a sequence of events resulting in structural and functional damage of the nervous tissue, comparable to that seen at other sites of vascular injury \[[@CR20]\]. Transient global cerebral ischemia of the rat results in a long-term increase in extracellular nucleotide hydrolysis pathways \[[@CR242], [@CR243]\]. Preconditioning delays the postischemic increase in ATP diphosphohydrolase activity \[[@CR243]\]. During the days following transient forebrain ischemia, mRNA for NTPDase1 (but not of NTPDase2) and ecto-5′-nucleotidase becomes upregulated in the hippocampus \[[@CR242]\], corresponding to the upregulation of the entire ectonucleotidase chain for the hydrolysis of ATP to adenosine. The data suggest that the increased expression of ectonucleotidases in the regions of damaged nerve cells is associated with activated glia, mainly microglia \[[@CR224]\].

The upregulation of the ectonucleotidase chain is suggestive of an ischemia-induced increased and sustained cellular release of nucleotides. This could have several functional implications. Since microglial cells express the cytolytic P2X~7~ receptor \[[@CR244], [@CR245]\] the activity of these cells may be particularly endangered by increased levels of extracellular ATP. Enhanced activity of NTPDase1 may prevent activated microglia from overstimulation by ATP released from the injured tissue. Alternatively, microglial expression of NTPDase1 might contribute to preventing receptor desensitization on prolonged exposure to elevated ATP levels. The parallel increase in activity of ecto-5′-nucleotidase would facilitate the formation of the final hydrolysis product adenosine that exerts neuro-modulatory and immunomodulatory actions and contributes to the protection of neurons.

Alterations following plastic changes in the nervous system {#Sec28}
-----------------------------------------------------------

Additional experiments, analyzing synaptosome fractions, suggest that changes in neural plasticity can be paralleled by changes in ecto-ATPase activity. Enzyme activity is reduced following avoidance learning \[[@CR246]\] and status epilepticus \[[@CR247], [@CR248]\]. It is altered in two rat models of temporal lobe epilepsy \[[@CR249]\], and on pentylenetetrazol kindling \[[@CR250]\]. Changes in synaptosomal ectonucleotidase activity have been implicated by a broad variety of additional treatments including acute caffeine treatment \[[@CR251]\]. Taken together, these experiments suggest that expression of ectonucleotidases can be altered following a variety of physiological or pathological stimuli, possibly together with that of purine receptors. Further work needs to define the enzyme subtypes involved and the mechanisms underlying the regulation of ectonucleotidase expression.

Conclusions {#Sec29}
===========

This review summarizes components of extracellular nucleotide-mediated signaling pathways that are impacted upon largely by the E-NTPDase family of ectonucleotidases. Modulated, distinct NTPDase expression appears to regulate nucleotide-mediated signaling in essentially every tissue, including the vasculature and of immune and nervous systems. For example, extracellular nucleotide-mediated vascular endothelial and accessory cell stimulation might have important consequences for platelet activation, thrombogenesis, angiogenesis, vascular remodeling and the metabolic milieu of the vasculature, in response to inflammatory stress and/or immune reactions.

Nucleotides are also of significant relevance for the communication of nerve cells and glial cells or in the reciprocal signaling between these cells. These purinergic mechanisms might also dictate pathological processes of the nervous system or following vascular injury, thromboregulatory disturbances, and defective angiogenesis with associated perturbations in tissue remodeling and regeneration.

There is a wide field for future investigations of the role of nucleotides and ectonucleotidases in other tissues. Increasing interest in this field may open up new avenues for investigation and the development of new treatment modalities for a large variety of diseases, including neurological pathological states, vascular thrombotic disorders including stoke, atherosclerosis and the vascular inflammation seen in transplant-graft failure.
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:   ecto-nucleoside triphosphate diphosphohydrolase

ERK

:   extracellular regulated kinase

FAK

:   focal adhesion kinase

MAP

:   mitogen-activated protein

MAPK

:   MAP kinase

NO

:   nitric oxide

NPP

:   nucleotide pyrophosphatase/phosphodiesterase

NTPDase

:   nucleoside triphosphate diphosphohydrolase

PDGF

:   platelet derived growth factor

PI3K

:   phosphatidylinositol 3-kinase

RanBPM

:   ran binding protein

TCDD

:   tetrachlorodibenzo-*p* dioxin
